ReviewStem cell reviews and reports2026
Exploring Stem Cell Based Senotherapeutic Strategies for Targeting Cellular Senescence in Brain Aging.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence is characterized by a state of stable proliferation arrest which ultimately leads to decline in the regenerative potential of cells, tissues and organ. Several factors like oxidative stress, DNA damage, neuroinflammation, and altered proteostasis mark the onset of cellular senescence. A growing body of evidence highlights a strong association between cellular senescence and the development of neurodegenerative disorders, where the accumulation of senescent cells contribute to chronic inflammation, tissue dysfunction, and progressive neuronal degeneration. Despite significant advances in understanding brain aging, effective therapeutic strategies targeting these mechanisms remain limited. Over the years, targeting cellular senescence has emerged as a promising strategy in the development of senotherapeutics for age-associated neurodegenerative diseases. Stem cells and their acellular derivatives, such as the secretome, extracellular vesicles, and mitochondria, have recently emerged as promising senotherapeutic candidates. As evidenced from previous reports, cell-free components of stem cells may confer senotherapeutic benefits by delivering bioactive molecules and maintaining tissue microenvironmental homeostasis to rejuvenate the senescent cells. However, previous reviews have predominantly focussed on senotherapeutics and role of stem cells as antiaging agents. There remains a lack of integrated understanding of their role in modulating brain aging and neurodegeneration. In this review, we discuss the mechanistic role of cellular senescence in neurodegeneration contributing to brain aging and highlight emerging insights into stem cell and its acellular products as potential senotherapeutic strategies. Furthermore, we have highlighted some therapeutic strategies based on acellular products of stem cells in for combating age-associated brain dysfunction. Our manuscript uniquely provides a comprehensive essay on mechanistic insights, therapeutic convergence, and translational implications.
Indexed as
Identifiers
41973384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.